In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

TyRx Pharma gets $25mm through its Series E round

Executive Summary

TyRx Pharma (drug-eluting devices) has raised $25mm through the closing of its Series E venture round. Clarus Ventures and Pappas Ventures co-led the financing and will each gain representation on the company's board. TyRx will use the money to launch its recently FDA-cleared AIGISrx, an implantable device that holds a pacemaker or implantable cardioverter defibrillator in place and contains the antibacterial compounds rifampin and minocycline to lower the risk of infections.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies